论文部分内容阅读
目的研讨冠心病合并心衰患者合用曲美他嗪与美托洛尔治疗的临床价值。方法从我院2015年1月-2016年12月选取76例冠心病合并心衰患者进行临床试验,并随机分组(38例/组),Ⅰ组单纯接受美托洛尔片口服,Ⅱ组同时使用曲美他嗪治疗,对两组的临床药效、心功能改善情况等作评估。结果Ⅰ、Ⅱ组的临床总有效率各为78.9%与94.7%,数据相比,差异显著(P<0.05)。治疗前,两组的LVEF、LEVDD及LEVSD评测值相比,差异不显著(P>0.05);治疗后,Ⅱ组上述心功能指标评测值均显著改善,与Ⅰ组相比差异显著(P<0.05)。结论合用曲美他嗪与美托洛尔对冠心病合并心衰患者进行治疗具有显著药效,且可有效促进患者心功能的恢复,值得加强推广。
Objective To investigate the clinical value of trimetazidine combined with metoprolol in patients with coronary heart disease complicated with heart failure. Methods From January 2015 to December 2016, 76 patients with coronary heart disease complicated with heart failure were selected and randomly divided into three groups: group Ⅰ received metoprolol tablets orally, while group Ⅱ The use of trimetazidine treatment, the two groups of clinical efficacy, improvement of cardiac function for assessment. Results The total clinical effective rates in groups Ⅰ and Ⅱ were 78.9% and 94.7%, respectively, with significant difference (P <0.05). Before treatment, there was no significant difference in LVEF, LEVDD and LEVSD between the two groups (P> 0.05). After treatment, the scores of cardiac function in group Ⅱ were significantly improved, with significant difference compared with group Ⅰ (P < 0.05). Conclusion Combination of trimetazidine and metoprolol in patients with coronary heart disease complicated with heart failure treatment has significant efficacy, and can effectively promote the recovery of patients with cardiac function, it is worth to strengthen the promotion.